“The Non-CME Corporate Forum content and views expressed therein do not necessarily reflect the views, policies or position of the American College of Allergy, Asthma & Immunology.”
Thursday, November 4, 2021
6:30PM – 7:00PM CT: Registration and Dinner
7:00PM – 8:30PM CT: Symposium
Hilton New Orleans Riverside
2 Poydras St
New Orleans, LA 70130
Meeting Room: Grand Ballroom A
Program Features
- iPads provided to all attendees to enhance learning experience and enable real-time Q&A
- Create your own personalized poster
- Interactive case-based learning environment
- Animated Simulation Treatment Challenges
Faculty
Donald Y M Leung, PhD, MD
Professor and Division Head
Pediatric Allergy & Immunology
Department of Pediatrics
National Jewish Health
Denver, CO
Peter A Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Chicago, IL
Learning Objectives
After completing this activity, learners should be better able to:
- Apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with atopic dermatitis during the COVID-19 pandemic
- Assess the severity of atopic dermatitis and select appropriate treatment options for patients who require intensified therapy
- Review the mechanism of action, efficacy and safety of systemic treatments for atopic dermatitis in pediatric and adult patients
Target Audience
This activity is intended for allergists, immunologists, and other healthcare professionals involved in the management of patients with atopic dermatitis.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
